Stock Day Media
Navidea Biopharmaceuticals, Inc. | Ekinops
Jul 10, 2024
· 0m
<div>Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company’s pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea’s Chief Medical Officer, said "Results are not indicative of a commercially viable product.”<br> <br> Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops …
ບົດນີ້ຍັງບໍ່ທັນໄດ້ຂຽນເປັນພາສາລາວເທື່ອ
ໃຊ້ STT.ai ເພື່ອແປບົດນີ້ດ້ວຍ AI. ໄດ້ຮັບຂໍ້ຄວາມທີ່ຖືກຕ້ອງກັບການກວດພົບຜູ້ເວົ້າ, ເວລາແລະສົ່ງອອກເປັນຮູບແບບຫຼາຍຮູບແບບ.
ກວດພົບຜູ້ເວົ້າ
ເວລາທີ່ໄດ້ຕັ້ງຄ່າໃນລະດັບຄໍາ
ສົ່ງອອກເປັນ SRT, TXT, JSON